Site Search
597 results for division 1 coins fc 26 Visit Buyfc26coins.com Szybkie dostawy nawet w weekendy..kHXp
- Our large case experts
- Individual insurance video library
-
Equitable Life Group Benefits Bulletin - April 2021
In this issue:
- Alberta biosimilar coverage changes*
- New Humira biosimilars approved*
- Saskatchewan and Manitoba delist biologics for some conditions*
Update: Alberta biosimilar coverage changes take effect*
In our November 2020 edition of eNews, we announced we are changing coverage for some biologic drugs in Alberta in response to the province’s Biosimilar Initiative.
As of March 15, 2021, several originator biologic drugs are no longer covered for plan members in Alberta. Plan members taking these biologics are required to switch to the biosimilar versions of these drugs to maintain eligibility under their Equitable Life plan.
Affected drugs and conditions – Remicade remains eligible
We initially announced that Remicade would be among the biologic drugs no longer covered in Alberta.
We have since determined a method to maintain ongoing eligibility of Remicade while reducing or eliminating any Coordination of Benefit risk associated with the provincial change. As such, Remicade will continue to be eligible for coverage.
Communication to plan members and plan sponsors
We communicated directly with affected claimants in January 2021 to allow them ample time to change their prescriptions and avoid any interruptions in their treatment or their coverage. The transition to biosimilars, when required, has been smooth and continues to be successful.
Plan sponsors were notified even earlier to allow ample time to opt-out of this change. The vast majority have accepted the changes and are benefiting from a smooth plan member transition.
Looking ahead
We are one of the few insurers taking a comprehensive and proactive response to the Alberta Biosimilars Initiative. We will continue to monitor developments related to the coverage of biologics in Alberta and other provinces and will continue to take steps to protect your clients’ drug plans.
Questions?
If you have any questions about this change, please contact your Group Account Executive or myFlex Sales Manager.
New Humira biosimilars approved*
Beginning in February, Health Canada approved seven new biosimilars for Humira, a biologic drug for the treatment of rheumatoid arthritis, psoriatic arthritis, Crohn's disease and many other conditions. Most of these biosimilars have already been launched and are available in pharmacies.
Humira is one of the highest ranked drugs in terms of total annual cost. All the Humira biosimilars are priced 40% lower than Humira and represent a savings opportunity for private drug plans.
BC Pharmacare has already announced that, effective October 7, 2021, all claimants for most conditions will only be eligible for Humira biosimilars.
We have implemented national controls to ensure the use of Humira biosimilars for new claimants. As with all biosimilar programs at Equitable Life, they will continuously evolve such that our clients are provided appropriate risk protection.
Saskatchewan and Manitoba change coverage for some biologics*
The Saskatchewan government recently announced that, effective March 1, 2021, new patients will no longer be eligible for coverage of Enbrel under its public plan. New patients will only be eligible for biosimilar versions of Enbrel.
Similarly, the Manitoba government announced changes to its tiered biologics program. Currently, claimants are expected to try biosimilars listed under Tier 1 of the program before they can be considered for coverage under the public plan for either Enbrel or Remicade, which are Tier 2 drugs. Effective April 1, 2021, Brenzys, an Enbrel biosimilar, has been added to Tier 1 for some additional medical conditions. As well, Avsola has been added as another Tier 1 biosimilar for Remicade. These changes further expand the Manitoba government’s utilization of biosimilars as preferred therapies over originator biologics.
Biosimilars are highly similar to the drugs they are based on and Health Canada considers them to be equally safe and effective for approved conditions.
Equitable Life actively monitors and investigates all biosimilar policy changes and the ongoing evolution of biosimilar drugs entering Canada. We will keep you informed of any impact on private drug plans and how we are responding.
*Indicates content that will be shared with your clients
- [pdf] Equitable Guaranteed Investment Funds Understanding sales charge options
- [pdf] Payout Annuity Interest Rate Guarantees (Advisor)
- [pdf] Coverage2go
- [pdf] Personalized Brochure - Benefits of segregated funds in a Tax-free Savings Account
-
Equitable Life Group Benefits COVID-19 Update
The test of a great partner is one who stands tall when you and your clients need to rely on them most. As the COVID-19 pandemic continues, we thought you might find it helpful to have a summary of where we are during this crisis.
You can download this PDF version to refer to when meeting with your clients.
We are here with you and for you
We’ve taken several steps to support you, your clients and their plan members during this crisis, including:
- Providing premium refunds for insured, non-refund Health and Dental benefits;
- Waiving the waiting period for short-term disability claimants who tested positive for COVID-19;
- Extending out-of-country travel coverage for plan members who were unable to return to Canada;
- Providing increased flexibility for premium payments; and
- Keeping you and your clients informed with timely Q&As and announcements, webinars, and insights into the impact of COVID-19 on benefits plans.
As well, to commemorate our 100th Anniversary this year, we donated $4.5 million to purchase and install a new MRI for Grand River Hospital. And we donated $50,000 – $10,000 each – to five charities in British Columbia, Alberta, Manitoba, Ontario and Quebec. For more information about our celebrations, check out our website at www.equitable100.ca.
We have adjusted our business to become digital
Our business is near 100% digital, so the vast majority of our employees are now working remotely from home and are fully functional. Since the pandemic began, our IT and operations teams have digitally enhanced more than 20 different processes and services to make it easier for us to integrate with our distribution partners in this new reality.
We pride ourselves on our customer service
In 2019, our dedication to customer service was recognized with outstanding survey results.
- In a 2019 survey of customers from 15 life insurance companies,1 Equitable Life ranked #1 on the Net Promoter Score, a measure used across industries to gauge the loyalty of a firm's customer relationships; and
- A survey of Group consultants, brokers and third-party administrators 2 ranked Equitable Life in the top two insurers across all categories.
For 2020, we continue to deliver service at the same level with no disruptions during this crisis. Our Customer Care Centre remains open to support plan members and can be reached at 1.800.265.4556. And our Client Relationship Specialists are available for Plan Administrator questions and support.
We are financially strong and stable
We remain financially strong and continue to focus on meeting the needs of Canadians. At the end of the first quarter, our Life Insurance Capital Adequacy Test (LICAT) ratio is at 152.5%, well above our goal and the regulatory requirement.
As the global situation continues to evolve, rest assured that Equitable Life is unwavering in our commitments to you and the communities we serve. We are here with you and for you. Please contact your Group Account Executive or myFlex Sales Manager if you have questions or need assistance.
1 LIMRA CxP Customer Experience Benchmarking Program, Life Insurance In-Force Experience 2019
2 NMG Consulting’s Canadian Group Benefits Survey 2019
- [pdf] Borrowing Money to Make Money
- Life Policy Collateral Loans